Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) EBIT Margin (2020 - 2023)

Gain Therapeutics has reported EBIT Margin over the past 4 years, most recently at 9477.68% for Q1 2023.

  • Quarterly results put EBIT Margin at 9477.68% for Q1 2023, down 217093.0% from a year ago — trailing twelve months through Dec 2023 was 40328.26% (down 2764016.0% YoY), and the annual figure for FY2023 was 40328.26%, down 2764016.0%.
  • EBIT Margin for Q1 2023 was 9477.68% at Gain Therapeutics, down from 5442.98% in the prior quarter.
  • Over the last five years, EBIT Margin for GANX hit a ceiling of 4306.17% in Q2 2021 and a floor of 46819.42% in Q1 2021.
  • Median EBIT Margin over the past 4 years was 8829.61% (2021), compared with a mean of 13188.97%.
  • Biggest five-year swings in EBIT Margin: tumbled -3914281bps in 2021 and later surged 3951266bps in 2022.
  • Gain Therapeutics' EBIT Margin stood at 17678.47% in 2020, then skyrocketed by 50bps to 8829.61% in 2021, then surged by 38bps to 5442.98% in 2022, then tumbled by -74bps to 9477.68% in 2023.
  • The last three reported values for EBIT Margin were 9477.68% (Q1 2023), 5442.98% (Q2 2022), and 7306.75% (Q1 2022) per Business Quant data.